Home > Drugs A – Z > Aflibercept (Into the eye)

Aflibercept (Into the eye)

What works?

Learn more about the effects of these drugs. The most reliable research is summed up for you in our featured article.

Aflibercept injection is used to treat neovascular (wet) age-related macular degeneration (AMD). AMD is a disorder of the retina in the eye that causes blurred vision or blindness. Aflibercept works by changing the amount of blood that gets to the retina. Aflibercept injection is also used to treat macular edema after retinal vein occlusion. It is also used to treat diabetic macular edema (DME)… Read more
Brand names include
Eylea
Drug classes About this
Ophthalmologic Agent

What works? Research summarized

Evidence reviews

Aflibercept (Eylea, New Therapeutic Indication) -- Benefit Assessment According to §35a Social Code Book V [Internet]

The aim of this report was to assess the added benefit of aflibercept (Eylea) for the treatment of adults with visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO) in comparison with the appropriate comparator therapy (ACT).

Aflibercept (Zaltrap) -- Benefit Assessment According to §35a Social Code Book V [Internet]

The aim of this report is to assess the added benefit of aflibercept in combination with a chemotherapy consisting of irinotecan / 5-fluorouracil / folinic acid (FOLFIRI) in comparison with FOLFIRI as appropriate comparator therapy (ACT) in adult patients with metastatic colorectal cancer (mCRC) that has progressed during or after an oxaliplatin-containing regimen. The comparator therapy chosen by the company concurs with the ACT specified by the Federal Joint Committee.

Aflibercept (Addendum to Commission A14-32) [Internet]

On 28 January 2015, the Federal Joint Committee (G-BA) commissioned the Institute for Quality and Efficiency in Health Care (IQWiG) to conduct a supplementary assessment for Commission A14-32 (Aflibercept (new therapeutic indication) – Benefit assessment according to §35a Social Code Book (SGB) V).

See all (36)

Summaries for consumers

Aflibercept (Eylea) for myopic choroidal neovascularization: Overview

The drug aflibercept (trade name Eylea) has been approved in Germany since October 2015 for adults with declining eye-sight due to myopic choroidal neovascularization.

Aflibercept (Eylea) for age-related macular degeneration: Overview

The drug aflibercept (trade name: Eylea) has been approved in Germany since November 2012 for the treatment of neovascular (wet) age-related macular degeneration (AMD) in adults.

Aflibercept (Eylea) for macular edema following retinal vein occlusion: Overview

The drug aflibercept (trade name: Eylea) is approved in Germany for the treatment of loss of eyesight due to macular edema in adults.

See all (13)

PubMed Health Blog...

read all...